- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01457885
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen (CloBu4)
Multi-center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-remission Acute Myeloblastic Leukemia (AML) Using Clofarabine and Busulfan x 4 (CloBu4) Regimen
Although transplant results for AML in complete remission (CR) at the time of transplant have improved, transplant results for non-remission AML have been quite poor. Most multi-center studies have focused on standard risk AML patients and not many studies have been done in this population of patients with non-remission AML. There are a large number of older patients with non-remission AML because the complete remission rate with induction chemotherapy decreases with age. Such older patients do not tolerate conventional full intensity conditioning regimens. Thus, an effective and tolerable conditioning regimen for non-remission AML is a great unmet need for current transplant practice.
From the investigators earlier study, it is suggested that replacing Fludarabine of standard FluBu4 regimen by Clofarabine (a related drug with much more potent anti-leukemia effect) in the transplant conditioning regimen may potentiate the anti-tumor activity of the conditioning regimen without adding significant toxicity, a goal of new conditioning regimen development.
The investigators expect to enroll a total of 75 patients from about fifteen sites. The investigators main objective is to confirm both the safety and efficacy as measured by one-year overall survival, of the CloBu4 combination as full intensity conditioning for non-remission acute myelogenous leukemia.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama, Birmingham
-
-
California
-
Duarte, California, United States, 91010
- City of Hope National Medical Center
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University at St Louis
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbuilt University
-
-
Washington
-
Seattle, Washington, United States, 98109
- University of Washington
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Disease Criteria
AML not in remission at the time of transplant
- "Not in remission" is defined as "greater than 5.0% bone marrow blasts by aspirate morphology," as determined by a bone marrow aspirate obtained within 2 weeks of study registration.
- For primary induction failure patients: Patients must have failed at least 2 induction regimens.
- For patients with relapsed disease: Patients who relapse more than 6 months after preceding remission must fail at least one reinduction regimen to be eligible. For patients in whom the preceding remission is equal to or shorter than 6 months duration, no re-induction regimen is required to qualify for this protocol.
- If the pre-transplant bone marrow aspirate and biopsy are hypoplastic (less than 10% cellularity), and blast percentages cannot be determined, the patient is eligible if the preceding bone marrow met the above criteria.
- Patients with peripheral circulating blasts or patients with extramedullary leukemia are eligible if bone marrow aspirate and biopsy meets the above criteria. Age and Organ Function Criteria
- Age: 2 to 65 years in age.
- Cardiac: LVEF ≥ 40% by MUGA (Multi Gated Acquisition) scan or echocardiogram.
- Pulmonary: FEV1 and FVC capacity) ≥ 40% predicted, DLCO (corrected for hemoglobin) ≥ 40% of predicted.
- Children who are unable to cooperate for pulmonary function tests (PFTs), must have no evidence of dyspnea at rest, no exercise intolerance, and not require supplemental oxygen therapy.
- Renal: Age equal to or older than 12: The estimated creatinine clearance (CrCl) must be equal or greater than 60 mL/min/1.73 m2 as calculated by the Cockcroft-Gault Formula. Age younger than 12: Either estimated or measured CrCl should be greater than 90 ml/min/1.73m2. For estimation, Schwartz formula will be used.
- Hepatic: Serum bilirubin ≤ 1.5 x upper limit of normal (ULN); (AST)/ ALT ≤ 2.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN
- Performance status: Karnofsky ≥ 70%., or Lansky≥70% Consent: All patients must sign informed consent
Exclusion Criteria:
- Active life-threatening cancer requiring treatment other than AML
- Non-compliant to medications.
- No appropriate caregivers identified.
- HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive
- Active life-threatening cancer requiring treatment other than AML
- Uncontrolled medical or psychiatric disorders.
- Uncontrolled infections, defined as positive blood cultures within 72 hours of study entry, or evidence of progressive infection
- Active central nervous system (CNS) leukemia
- Preceding allogeneic HSCT
- Receiving intensive chemotherapy within 21 days of registration.
- Patients with preceding primary myelofibrosis
- Peripheral blasts > 10,000/μL at the time of registration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CloBu4 regimen
After pre-conditioning with CloBu4 (Clofarabine/Busulfan x 4), subjects will receive a peripheral blood stem cell transplant
|
Peripheral blood stem cell transplant, after pre-conditioning drug treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Incidence of Non Relapse Mortality (NRM)
Time Frame: 1 year
|
Percentage of patients passed without relapse/recurrence at 1 year.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Percentage of Patients Alive at 1 Year
Time Frame: 1 year
|
Overall survival was calculated following transplant using a CloBu4 conditioning regimen for patients with non-remission AML
|
1 year
|
Incidence of Relapse
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Investigators
- Study Chair: Shin Mineishi, MD, University of Alabama at Birmingham
- Principal Investigator: John M Magenau, MD, University of Michigan, Department of Internal Medicine
- Study Chair: Stephen J Forman, MD, City of Hope National Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Clofarabine
- Busulfan
Other Study ID Numbers
- UMCC 2011.038
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloblastic Leukemia
-
PETHEMA FoundationRecruitingAcute Myeloblastic LeukemiaSpain
-
Goethe UniversityCompletedAcute Myeloblastic LeukemiaGermany
-
PETHEMA FoundationCompleted
-
University Hospital, BordeauxRecruitingAcute Myeloblastic LeukemiaFrance
-
PETHEMA FoundationCompleted
-
PETHEMA FoundationCompletedAcute Myeloblastic LeukaemiaSpain
-
Instituto de Investigación Sanitaria de la Fundación...CompletedHematopoietic Stem Cell Transplantation | Acute Myeloblastic LeukemiaSpain
-
PETHEMA FoundationCompleted
-
Nantes University HospitalNot yet recruitingAdult Patients With Adverse Risk Acute Myeloblastic Leukemia
-
Assistance Publique - Hôpitaux de ParisUnknownAcute Myeloblastic Leukemia | Aged Higher Than 60 Years OldFrance
Clinical Trials on Peripheral blood stem cell transplant
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityAvailableMalignant Neoplasm | Hematopoietic Cell Transplantation Recipient | Benign Neoplasm | Bone Marrow Transplantation RecipientUnited States
-
The Cooper InstituteCargillCompleted
-
Emory UniversityTerminatedRecurrent Solid Tumors | High Risk Solid TumorsUnited States
-
Northside Hospital, Inc.Blood and Marrow Transplant Group of GeorgiaCompletedTotal Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic DiseasesNon-Hodgkin's Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Chronic Leukemia | Hodgkin's DiseaseUnited States
-
Azienda Ospedaliera San Giovanni BattistaCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawn
-
Sidney Kimmel Cancer Center at Thomas Jefferson...WithdrawnAnemia | Thrombocytopenia | Neutropenia | Hematopoietic/Lymphoid Cancer | Lymphopenia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Terminated
-
St. Jude Children's Research HospitalCompletedAnemia, Aplastic | Diamond-Blackfan Anemia | Amegakaryocytic Thrombocytopenia | Kostmann SyndromeUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Malignancies | Bone Marrow Transplant RejectionUnited States